Candel Therapeutics: An Overlooked Late-Stage Biotech With Real Potential

FDA Clears a Transplant Therapy Built to Cut Chronic GVHD From 44% to 13%

The FDA approved Tregzi, Orca Bio's engineered cell therapy, after a 187-patient trial found it cut moderate-to-severe chronic graft-versus-host disease from 44 with standard transplants to 13. The tradeoff patients now face is a newer therapy without years of follow-up data behind it.

Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?

The company recently wowed investors with clinical trial results.

Angiex’s Upcoming Mission on the International Space Station

I think most of you know that the reason we haven’t been posting much the last three years is that Shou-Ching and I launched a biotech company, Angiex, in 2015 with the goal of creating a breakthrough cancer therapy. Our Read more » The post Angiex’s Upcoming Mission on the International Space Station appeared first on Perfect Health Diet.

Lupin gets tentative US FDA nod for Enzalutamide tablets

The US FDA has tentatively approved Lupin’s Enzalutamide Tablets in 40 mg and 80 mg as bioequivalent to Astellas’ Xtandi Tablets for the approved indication

Suzanne Reisler Litwin: Showing up … for the Breakthrough T1D Walk to cure type 1 diabetes

Suzanne Reisler Litwin: Showing up … for the Breakthrough T1D Walk to cure type 1 diabetes

Celltrion secures FDA’s 1st interchangeable status for Rituximab biosimilar

Celltrion secures FDA’s 1st interchangeable status for Rituximab biosimilar

5 of America's greatest medical breakthroughs revealed as the nation marks 250 years

From joint replacement and Deep TMS for depression to targeted therapy for cancer, experts highlight top U.S. medical breakthroughs over 250 years.

Lyell at H.C. Wainwright cell therapy conference: data and catalysts

Lyell at H.C. Wainwright cell therapy conference: data and catalysts

NervGen Pharma: I Think The Biggest Risks Are Now Behind It

NervGen Pharma: I Think The Biggest Risks Are Now Behind It

Trisha Goddard reveals health update amid stage 4 breast cancer diagnosis

Trisha Goddard has shared a health update with her Instagram followers amid her breast cancer diagnosis. The 68-year-old television presenter was diagnosed with secondary breast cancer - also known as metastatic or stage 4 breast cancer – in July 2022.

Review Identifies 16 Medicinal Plants With Potential Antidiabetic Effects

(NaturalNews) A review published June 3, 2026 in The Open Biochemistry Journal examined 16 medicinal plants traditionally used for diabetes. Researchers found the p...

New drug offers hope to MND patients

A drug developed in Queensland offers a breakthrough in the treatment of MND.

Ivermectin isn't a cancer miracle drug, but influencers claim otherwise -- here's how to avoid sprinting past scientific evidence

Ivermectin isn't a cancer miracle drug, but influencers claim otherwise -- here's how to avoid sprinting past scientific evidence

The Hidden Reason Biotech Breakthroughs Keep Getting Delayed

The real drug development delay? Bad communication.

Drybar Founder, 51, Debuts Stunning Before-and-After Facelift Photos

Sarmela Sunder, MD and Sunder Plastic SurgeryDrybar co-founder Alli Webb has finally gotten the facelift she says she spent years waiting for.The 51-year-old entrepreneur went back to her trusted Beverly Hills plastic surgeon, Dr. Sarmela Sunder, for a rhinoplasty and facelift after years of trying less invasive age-reversing treatments.Webb, who sold her highly popular chain of blowout bars to Helen of Troy in 2019 for 255 million, is now proudly debuting the results of her latest transformation.Read more at The Daily Beast.

‘Unprecedented spike’ in new synthetic drugs: UN watchdog

‘Unprecedented spike’ in new synthetic drugs: UN watchdog

New synthetic cells tiptoe toward creating life

New synthetic cells tiptoe toward creating life

Bee Venom vs Triple-Negative Breast Cancer: Why This Lab Study Matters

Honeybee Venom Breast Cancer Study – Why It Still Matters Image by Massimo @Rainmaker1973XMore than five years after its publication, a 2020 lab...

FDA Approves Trodelvy, A Breakthrough Treatment For One Of The Deadliest Breast Cancers

The FDA's approval of Trodelvy, a targeted treatment, could bring new hope for Black women battling metastatic triple-negative breast cancer.

Scientists Made a Gum Disease Gel from Jackfruit Latex, Pomegranate Peel, and Simvastatin — Fights Infection, Reduces Inflammation, and Regrows Bone

ScienceDaily June 19, 2026: PUC-SP researchers made a biomaterial from jackfruit latex, pomegranate peel, and simvastatin that fights gum disease infection while regrowing bone within 14 days.

Mexican researcher Nora Vázquez Laslop helps drive breakthrough antibiotic discovery

The research project that brought together scientists from Canada, the United States, Germany and Mexico identified a novel antibiotic that weakens the ability of harmful bacteria to develop resistance to it. The post Mexican researcher Nora Vázquez Laslop helps drive breakthrough antibiotic discovery appeared first on Mexico News Daily

Biohacker Bryan Johnson reveals incurable stomach condition

Biohacker and former tech CEO Bryan Johnson says he has autoimmune gastritis and calls it "incurable," vowing to find a cure. Read more: https://tinyurl.com/ykc3sefr Sign up for our newsletter for the day's top stories, from sports to movies to politics to world events: https://profile.usatoday.com/newsletters/daily-briefing/

FDA Reviews Sandoz Generic Obesity Drug Applications

The U.S. Food and Drug Administration (FDA) has accepted for review two generic versions of tirzepatide developed by Swiss pharmaceutical company Sandoz, a move that could pave the way for increased competition in the rapidly expanding obesity and diabetes treatment market. If approved, the medicines would become direct competitors to Eli Lilly’s blockbuster tirzepatide brands, [] The post FDA Reviews Sandoz Generic Obesity Drug Applications appeared first on Voice of Nigeria.

America's 250-Year Foundation for Biopharmaceutical Leadership

America's 250-Year Foundation for Biopharmaceutical Leadership